Table 3. Post-progression therapy for 13 patients treated following clinical trial completion.

Study Number	CIMP Status	Post-Progression Therapy	Time from Azacitdine study completion to next treatment (days)	Best Response	Time to progression (days)
3	CIMP-High	5-FU + Oxaliplatin + Bevacizumab + Cetuximab	19	PD	61
21	CIMP-High	Erlotinib	1	PD	60
19	CIMP-High	Irinotecan	1	PD	76
24	CIMP-High	Regorafenib	29	PD	46
25	CIMP-High	Regorafenib	22	PD	44
26	CIMP-High	Regorafenib	1	SD	439
11	non-CIMP	AMG 208 (c-MET inhibitor)	32	PD	34
12	non-CIMP	Bevacizumab + Lenalidomide	51	PD	55
7	non-CIMP	Cetuximab + Erlotinib + Bevacizumab	52	SD	111
13	non-CIMP	Erlotinib + Bortezomib	32	PD	60
14	non-CIMP	FOLFOX + Cetuximab + Dasatinib	40	PD	60
6	non-CIMP	GDC-0449 (hedgehog inhibitor)	61	PD	45
9	Unknown	Irinotecan + Bevacizumab + Cetuximab	26	PD	45